Vaccination of antibody deficient patients with Prevenar13 - a comparative study between antibody response and cellular immunity [Konjugerat pneumokockvaccin till patienter med antikroppsbrist – en studie for att jamfora antikroppssvar och cellular immunitet]
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2017
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Acronyms PNEUMOCELL
- 11 Apr 2017 Results published in the Vaccine
- 13 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 09 May 2013 Planned end date (Dec 2014) added as reported by ClinicalTrials.gov.